Oncology Pharma, Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating COVID-
Oncology Pharma and Kalos
Therapeutics Expand Licensing Agreement for Exploring Kalos's
Anti-Cancer Lead Drug in Treating COVID-19
SAN FRANCISCO, CA -- April 6, 2020 -- InvestorsHub NewsWire --
Oncology Pharma, Inc. (ONPH)
and Kalos Therapeutics (“Kalos”) announced today that the companies
amended the terms of their collaboration to explore treatment
opportunities of the COVID-19 virus, for the benefit of the most
vulnerable cancer patients with cardiovascular issues and/or a
weakened immune system.
George Colberg, Chairman and CEO of Kalos Therapeutics, and Dr.
Vijay Mahant, Chief Scientific Officer of Oncology Pharma, have
proposed the investigation of Kalos Therapeutics’ lead drug
KTH-222 (alone and/or in combination with anti-viral drugs) as an
integral part of monitoring viral loads in cancer patients infected
with the COVID-19 virus or in suspected patients with the symptoms.
"We believe the expansion of this agreement is a proactive step
forward in advancing therapies, risk mitigation and our commitment
in healthcare. The co-development program between the two companies
and the potential for KTH-222 as a mono-therapy and/or in
combination with FDA-approved or compassionate anti-viral therapies
together with Oncology Pharma's diagnostic expertise in combating
COVID-19 in vulnerable cancer patients will potentially benefit
such patients,” Colberg stated.
Jamie Jones, Chief Business Officer at Kalos Therapeutics, said,
"Under the terms of the amended co-development and licensing
agreement between Kalos and Oncology Pharma, we will assess our
businesses thoroughly to create collaborations for better
efficiency. We expect, if successful, the outcome to improve access
to capital, and most importantly, expedite our drug and diagnostic
development practices to meet patient needs.”
In 2019, Kalos Therapeutics signed a Letter of Intent with
Oncology Pharma, for a worldwide license and co-development of
Kalos's lead anti-cancer drug, KTH-222. The agreement
centered on KTH-222 as a mono-therapy and/or in combination with
antiviral drugs or therapies approved by the FDA and/or the
appropriate regulatory agencies.
Kalos Therapeutics is developing a platform of drugs containing
multiple arrays of a natriuretic peptide, which have demonstrated a
broad spectrum of anti-tumor activity with negligible or no known
adverse effects. In a Pre-IND study using the parent drug involving
a total of 88 patients, including 22 healthy patients, the study
demonstrated safety and therapeutic efficacy. Kalos's leading drug
candidate, KTH-222, regulates cell growth via inhibition of the
mitogen-activated protein kinase (MAPK) pathway. Kalos’s vision is
to change the care paradigm for treating cancer patients as KTH-222
can be a lead therapy, or used in combination with existing
treatments to improve efficacy and reduce toxicity, and mitigate
resistance or reverse it.
ABOUT ONCOLOGY PHARMA, INC.
Oncology Pharma, Inc. (ONPH)
(the "Company") is a pioneering oncology company dedicated to
developing, manufacturing, and commercializing therapeutics. The
Company has entered into Letters of Intent with Kalos Therapeutics
for its lead anticancer drug, KTH-222, Diagnomics (a CLIA and CAP
accredited molecular diagnostic lab), NanoSmart Pharmaceuticals for
its targeted drug delivery platform and a licensing agreement with
Ribera Solutions for its Connect2Med clinical trial app
ABOUT KALOS THERAPEUTICS, INC.
Kalos is pursuing a multi-phase strategy to reorient today's
therapeutic approach to cancer patients while driving changes to
transform therapeutic approaches for unmet and rare medical
conditions. Kalos has a lead compound KTH-222, which is more
promising than "standard of care" drugs with difficult to treat
Kalos is devoted to treating the unmet needs of people living
with incurable diseases while doing so with less toxic and
debilitating side effects commonly associated with chemotherapies.
Kalos believes that by leveraging nature and all of the body's
mechanisms, they have created new, safer approaches to cancer and
diseases that affect the eye as well. Kalos has several
applications for animal health based on both its eight amino acid
and a 15 amino acid drug KTV-111. Kalos aims to treat dangerous and
debilitating diseases and improve the quality of life for the
patient and their families.
For additional information,
please contact the Oncology Pharma
One Sansome Street, Suite
San Francisco, CA